Prognostic value of ebv markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow‐up study
Between December 1979 and April 1982, 373 patients with untreated, undifferentiated carcinoma of the nasopharynx (NPC), 99 in Hong Kong, 120 in Tunis and 154 in Villejuif, entered a longitudinal study aimed at determining the clinical prognostic value of EBV serology after radiotherapy. A minimum of...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 1988-08, Vol.42 (2), p.176-181 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | 2 |
| container_start_page | 176 |
| container_title | International journal of cancer |
| container_volume | 42 |
| creator | De‐Vathaire, F. Sancho‐Garner, H. De‐Thé, H. Pieddeloup, C. Schwaab, G. Ho, J. H. C. Ellouz, R. Micheau, C. Cammoun, M. Cachin, Y. De‐Thé, G. |
| description | Between December 1979 and April 1982, 373 patients with untreated, undifferentiated carcinoma of the nasopharynx (NPC), 99 in Hong Kong, 120 in Tunis and 154 in Villejuif, entered a longitudinal study aimed at determining the clinical prognostic value of EBV serology after radiotherapy. A minimum of 3 years' follow‐up was achieved for 319 patients (83 in Tunis, 95 in Hong Kong and 141 in Villejuif) who had regular clinical and serological testing at intervals of 6–8 months. No significant difference in initial serology (i. e., before any treatment) or variations of antibody titers at time of first followup was observed between patients who achieved complete remission after radiotherapy and those who did not. This included IgG and IgA antibodies to VCA, EA or EBNA. However, when patients with confirmed clinical remission I year after completion of radiotherapy were studied, the value of IgG/EA and mainly of IgA/EA increasing titers became highly significant for prediction of relapse, regardless of the initial titers. This demonstrated the clinical usefulness of EBV serology for NPC patients who have confirmed clinical remission after radiotherapy. |
| doi_str_mv | 10.1002/ijc.2910420206 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78358883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78358883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3706-ea827363aee20b026a939d103ba4c9d6bb8a7ed1e27258fd369dff247bedca123</originalsourceid><addsrcrecordid>eNqFkLtOHDEUhq0oiGxI2nSR3IBCMRtf5uZ0aEWACAFFUo_OeM4sBo-9sWdAW0TKI-QZeRK82lVIl-pI5__8H-sj5ANnc86Y-Gzu9FwoznLBBCtfkRlnqsqY4MVrMksAyyouyzfkbYx3jHFesHyf7Is65yIvZuTXTfBL5-NoNH0AOyH1PcX2gQ4Q7jFEahwdb5Fqa5zRYNPewRIHdOOGdBD96hbC2i0xhRqCNs4PQD9d3SyOv9ATOkw2dSccA-29tf7x6fefaUXjOHXrd2SvBxvx_W4ekB9fT78vzrPL67OLxcllpmXFygyhFpUsJSAK1jJRgpKq40y2kGvVlW1bQ4UdR1GJou47Waqu70Vetdhp4EIekKNt7yr4nxPGsRlM1GgtOPRTbKpaFnVdywTOt6AOPsaAfbMKJqlYN5w1G99N8t28-E4PPu6ap3bA7i--E5zyw10OMenrAzht4kurKkpV8M1hteUejcX1f642F98W__zhGdzgm4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78358883</pqid></control><display><type>article</type><title>Prognostic value of ebv markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow‐up study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>De‐Vathaire, F. ; Sancho‐Garner, H. ; De‐Thé, H. ; Pieddeloup, C. ; Schwaab, G. ; Ho, J. H. C. ; Ellouz, R. ; Micheau, C. ; Cammoun, M. ; Cachin, Y. ; De‐Thé, G.</creator><creatorcontrib>De‐Vathaire, F. ; Sancho‐Garner, H. ; De‐Thé, H. ; Pieddeloup, C. ; Schwaab, G. ; Ho, J. H. C. ; Ellouz, R. ; Micheau, C. ; Cammoun, M. ; Cachin, Y. ; De‐Thé, G.</creatorcontrib><description>Between December 1979 and April 1982, 373 patients with untreated, undifferentiated carcinoma of the nasopharynx (NPC), 99 in Hong Kong, 120 in Tunis and 154 in Villejuif, entered a longitudinal study aimed at determining the clinical prognostic value of EBV serology after radiotherapy. A minimum of 3 years' follow‐up was achieved for 319 patients (83 in Tunis, 95 in Hong Kong and 141 in Villejuif) who had regular clinical and serological testing at intervals of 6–8 months. No significant difference in initial serology (i. e., before any treatment) or variations of antibody titers at time of first followup was observed between patients who achieved complete remission after radiotherapy and those who did not. This included IgG and IgA antibodies to VCA, EA or EBNA. However, when patients with confirmed clinical remission I year after completion of radiotherapy were studied, the value of IgG/EA and mainly of IgA/EA increasing titers became highly significant for prediction of relapse, regardless of the initial titers. This demonstrated the clinical usefulness of EBV serology for NPC patients who have confirmed clinical remission after radiotherapy.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.2910420206</identifier><identifier>PMID: 2841245</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Age Factors ; Antibodies, Viral - analysis ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Female ; Follow-Up Studies ; Herpesvirus 4, Human - immunology ; Humans ; Longitudinal Studies ; Male ; Medical sciences ; Middle Aged ; Nasopharyngeal Neoplasms - microbiology ; Otorhinolaryngology. Stomatology ; Prognosis</subject><ispartof>International journal of cancer, 1988-08, Vol.42 (2), p.176-181</ispartof><rights>Copyright © 1988 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3706-ea827363aee20b026a939d103ba4c9d6bb8a7ed1e27258fd369dff247bedca123</citedby><cites>FETCH-LOGICAL-c3706-ea827363aee20b026a939d103ba4c9d6bb8a7ed1e27258fd369dff247bedca123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.2910420206$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.2910420206$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19569513$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2841245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De‐Vathaire, F.</creatorcontrib><creatorcontrib>Sancho‐Garner, H.</creatorcontrib><creatorcontrib>De‐Thé, H.</creatorcontrib><creatorcontrib>Pieddeloup, C.</creatorcontrib><creatorcontrib>Schwaab, G.</creatorcontrib><creatorcontrib>Ho, J. H. C.</creatorcontrib><creatorcontrib>Ellouz, R.</creatorcontrib><creatorcontrib>Micheau, C.</creatorcontrib><creatorcontrib>Cammoun, M.</creatorcontrib><creatorcontrib>Cachin, Y.</creatorcontrib><creatorcontrib>De‐Thé, G.</creatorcontrib><title>Prognostic value of ebv markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow‐up study</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Between December 1979 and April 1982, 373 patients with untreated, undifferentiated carcinoma of the nasopharynx (NPC), 99 in Hong Kong, 120 in Tunis and 154 in Villejuif, entered a longitudinal study aimed at determining the clinical prognostic value of EBV serology after radiotherapy. A minimum of 3 years' follow‐up was achieved for 319 patients (83 in Tunis, 95 in Hong Kong and 141 in Villejuif) who had regular clinical and serological testing at intervals of 6–8 months. No significant difference in initial serology (i. e., before any treatment) or variations of antibody titers at time of first followup was observed between patients who achieved complete remission after radiotherapy and those who did not. This included IgG and IgA antibodies to VCA, EA or EBNA. However, when patients with confirmed clinical remission I year after completion of radiotherapy were studied, the value of IgG/EA and mainly of IgA/EA increasing titers became highly significant for prediction of relapse, regardless of the initial titers. This demonstrated the clinical usefulness of EBV serology for NPC patients who have confirmed clinical remission after radiotherapy.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Antibodies, Viral - analysis</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Herpesvirus 4, Human - immunology</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nasopharyngeal Neoplasms - microbiology</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Prognosis</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOHDEUhq0oiGxI2nSR3IBCMRtf5uZ0aEWACAFFUo_OeM4sBo-9sWdAW0TKI-QZeRK82lVIl-pI5__8H-sj5ANnc86Y-Gzu9FwoznLBBCtfkRlnqsqY4MVrMksAyyouyzfkbYx3jHFesHyf7Is65yIvZuTXTfBL5-NoNH0AOyH1PcX2gQ4Q7jFEahwdb5Fqa5zRYNPewRIHdOOGdBD96hbC2i0xhRqCNs4PQD9d3SyOv9ATOkw2dSccA-29tf7x6fefaUXjOHXrd2SvBxvx_W4ekB9fT78vzrPL67OLxcllpmXFygyhFpUsJSAK1jJRgpKq40y2kGvVlW1bQ4UdR1GJou47Waqu70Vetdhp4EIekKNt7yr4nxPGsRlM1GgtOPRTbKpaFnVdywTOt6AOPsaAfbMKJqlYN5w1G99N8t28-E4PPu6ap3bA7i--E5zyw10OMenrAzht4kurKkpV8M1hteUejcX1f642F98W__zhGdzgm4A</recordid><startdate>19880815</startdate><enddate>19880815</enddate><creator>De‐Vathaire, F.</creator><creator>Sancho‐Garner, H.</creator><creator>De‐Thé, H.</creator><creator>Pieddeloup, C.</creator><creator>Schwaab, G.</creator><creator>Ho, J. H. C.</creator><creator>Ellouz, R.</creator><creator>Micheau, C.</creator><creator>Cammoun, M.</creator><creator>Cachin, Y.</creator><creator>De‐Thé, G.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19880815</creationdate><title>Prognostic value of ebv markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow‐up study</title><author>De‐Vathaire, F. ; Sancho‐Garner, H. ; De‐Thé, H. ; Pieddeloup, C. ; Schwaab, G. ; Ho, J. H. C. ; Ellouz, R. ; Micheau, C. ; Cammoun, M. ; Cachin, Y. ; De‐Thé, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3706-ea827363aee20b026a939d103ba4c9d6bb8a7ed1e27258fd369dff247bedca123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Antibodies, Viral - analysis</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Herpesvirus 4, Human - immunology</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nasopharyngeal Neoplasms - microbiology</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De‐Vathaire, F.</creatorcontrib><creatorcontrib>Sancho‐Garner, H.</creatorcontrib><creatorcontrib>De‐Thé, H.</creatorcontrib><creatorcontrib>Pieddeloup, C.</creatorcontrib><creatorcontrib>Schwaab, G.</creatorcontrib><creatorcontrib>Ho, J. H. C.</creatorcontrib><creatorcontrib>Ellouz, R.</creatorcontrib><creatorcontrib>Micheau, C.</creatorcontrib><creatorcontrib>Cammoun, M.</creatorcontrib><creatorcontrib>Cachin, Y.</creatorcontrib><creatorcontrib>De‐Thé, G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De‐Vathaire, F.</au><au>Sancho‐Garner, H.</au><au>De‐Thé, H.</au><au>Pieddeloup, C.</au><au>Schwaab, G.</au><au>Ho, J. H. C.</au><au>Ellouz, R.</au><au>Micheau, C.</au><au>Cammoun, M.</au><au>Cachin, Y.</au><au>De‐Thé, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of ebv markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow‐up study</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>1988-08-15</date><risdate>1988</risdate><volume>42</volume><issue>2</issue><spage>176</spage><epage>181</epage><pages>176-181</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>Between December 1979 and April 1982, 373 patients with untreated, undifferentiated carcinoma of the nasopharynx (NPC), 99 in Hong Kong, 120 in Tunis and 154 in Villejuif, entered a longitudinal study aimed at determining the clinical prognostic value of EBV serology after radiotherapy. A minimum of 3 years' follow‐up was achieved for 319 patients (83 in Tunis, 95 in Hong Kong and 141 in Villejuif) who had regular clinical and serological testing at intervals of 6–8 months. No significant difference in initial serology (i. e., before any treatment) or variations of antibody titers at time of first followup was observed between patients who achieved complete remission after radiotherapy and those who did not. This included IgG and IgA antibodies to VCA, EA or EBNA. However, when patients with confirmed clinical remission I year after completion of radiotherapy were studied, the value of IgG/EA and mainly of IgA/EA increasing titers became highly significant for prediction of relapse, regardless of the initial titers. This demonstrated the clinical usefulness of EBV serology for NPC patients who have confirmed clinical remission after radiotherapy.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>2841245</pmid><doi>10.1002/ijc.2910420206</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 1988-08, Vol.42 (2), p.176-181 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78358883 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Age Factors Antibodies, Viral - analysis Biological and medical sciences Biomarkers, Tumor - analysis Female Follow-Up Studies Herpesvirus 4, Human - immunology Humans Longitudinal Studies Male Medical sciences Middle Aged Nasopharyngeal Neoplasms - microbiology Otorhinolaryngology. Stomatology Prognosis |
| title | Prognostic value of ebv markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow‐up study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A17%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20ebv%20markers%20in%20the%20clinical%20management%20of%20nasopharyngeal%20carcinoma%20(NPC):%20A%20multicenter%20follow%E2%80%90up%20study&rft.jtitle=International%20journal%20of%20cancer&rft.au=De%E2%80%90Vathaire,%20F.&rft.date=1988-08-15&rft.volume=42&rft.issue=2&rft.spage=176&rft.epage=181&rft.pages=176-181&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/ijc.2910420206&rft_dat=%3Cproquest_cross%3E78358883%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78358883&rft_id=info:pmid/2841245&rfr_iscdi=true |